Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer
Prostate Cancer
About this trial
This is an interventional supportive care trial for Prostate Cancer focused on measuring perioperative/postoperative complications, sexual dysfunction and infertility, sexuality and reproductive issues, adenocarcinoma of the prostate, stage I prostate cancer, stage II prostate cancer, prostaglandin E1, papaverine, phentolamine, Nerve-sparing radical prostatectomy, nerve grafting
Eligibility Criteria
Inclusion Criteria: Patient must be a candidate for a unilateral nerve sparing radical retropubic prostatectomy. a) Gleason score 7 or less in the cores on the side to be spared Patient must have no discernable preoperative erectile dysfunction, defined as the ability to have successful penetration on at least 75% of attempts. Patient must be </= 65 years of age at the time of study enrollment. Patient must have no peripheral neuropathy precluding procurement of a sural nerve graft Patient must have no significant psychiatric illness or demonstrable vasculogenic source of impotence. No prior history of pelvic irradiation or androgen deprivation therapy (LHRH agonists or anti-androgens) Exclusion Criteria:
Sites / Locations
- M.D. Anderson Cancer Center at University of Texas
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Arm I
Arm II (No sural nerve grafting)
Patients undergo unilateral cavernous nerve-sparing radical prostatectomy with unilateral autologous interposition sural nerve grafting.
Patients undergo unilateral cavernous nerve-sparing radical prostatectomy (without sural nerve grafting) and erectile dysfunction rehabilitation as in arm I.